Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeted Therapy for Melanoma.

Cancer treatment and research - 1 Jan 2016

Wong Deborah J L, Ribas Antoni

Abstract excerpt

Vemurafenib and dabrafenib, two potent tyrosine kinase inhibitors (TKIs) of the BRAF(V600E) kinase, are highly effective in the treatment of a BRAF (V600) -mutant metastatic melanoma. These are selective type I inhibitors (functional against the active conformation of the kinase) of the RAF kinases, which are key players in the mitogen-activated protein kinase (MAPK) pathway. BRAF (V600) mutations are present in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Mitogen-Activated Protein Kinase Kinases
Share to Molecular Targeted Therapy
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Share to Melanoma

Share to BRAF gene

Share to Immunotherapy

Source

Identifiers

PMID: 26601866
DOI: 10.1007/978-3-319-22539-5_10

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeted Therapy for Melanoma.PMID 26601866Read ↗

Update on the targeted therapy of melanoma.Semantic proximity Read ↗

Targeted therapy in BRAF‑mutant melanoma: Advances and challenges (Review).Semantic proximity Read ↗

Targeted therapies for cutaneous melanoma.Semantic proximity Read ↗

BRAF and MEK gene rearrangements in melanoma: implications for targeted therapy.Semantic proximity Read ↗

Targeted Therapy Innovations for Melanoma.Semantic proximity Read ↗

Emerging insights into resistance to BRAF inhibitors in melanoma.Semantic proximity Read ↗

Targeting mutant BRAF in melanoma: current status and future development of combination therapy strategies.Semantic proximity Read ↗

Targeted therapeutic strategies for melanoma.Semantic proximity Read ↗

Trametinib in the treatment of melanoma.Semantic proximity Read ↗

Emerging targeted therapies for melanoma.Semantic proximity Read ↗

Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma.Semantic proximity Read ↗

BRAF targeted therapy changes the treatment paradigm in melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.